Literature DB >> 26956146

LOOKING BACK ON 5 YEARS OF HORIZON SCANNING IN ONCOLOGY.

Anna Nachtnebel1, Johanna Breuer2, Wolfgang Willenbacher3, Anna Bucsics4, Peter Krippl5, Claudia Wild2.   

Abstract

OBJECTIVES: The regularly structured adaptation of health technology assessment (HTA) programs is of utmost importance to sustain the relevance of the products for stakeholders and to justify investment of scarce financial resources. This study describes internal adjustments and external measures taken to ensure the Horizon Scanning Programme in Oncology (HSO) is current.
METHODS: Formal evaluation methods comprising a survey, a download, an environmental analysis, and a Web site questionnaire were used to evaluate user satisfaction.
RESULTS: The evaluation showed that users were satisfied with HSO outputs in terms of timeliness, topics selected, and depth of information provided. Discussion of these findings with an expert panel led to changes such as an improved dissemination strategy and the introduction of an additional output, that is, the publication of a league table of emerging oncology drugs. The rather high level of international usage and the environmental analysis highlighted a considerable overlap in topics assessed and, thus, the potential for international collaboration. As a consequence, thirteen reports were jointly published based on eleven "calls for collaboration." To further facilitate collaboration and the usability of reports for other agencies, HSO reports will be adjusted according to tools developed at a European level.
CONCLUSIONS: Evaluation of the impact of HTA programs allows the tailoring of outputs to fit the needs of the target population. However, within a fast developing HTA community, estimates of impact will increasingly be determined by international collaborative efforts. Refined methods and a broader definition of impact are needed to ultimately capture the efficiency of national HTA programs.

Keywords:  Awareness; Biomedical; Cooperative behavior; Health policy; Program evaluation; Technology assessment

Mesh:

Substances:

Year:  2016        PMID: 26956146     DOI: 10.1017/S0266462316000052

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  5 in total

1.  Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?

Authors:  Nicole Grössmann; Claudia Wild
Journal:  ESMO Open       Date:  2017-01-31

2.  Scanning the horizon: a systematic literature review of methodologies.

Authors:  Philip Hines; Li Hiu Yu; Richard H Guy; Angela Brand; Marisa Papaluca-Amati
Journal:  BMJ Open       Date:  2019-05-27       Impact factor: 2.692

3.  Pre-reimbursement: early assessment for coverage decisions.

Authors:  Nicole Grössmann; Sarah Wolf; Katharina Rosian; Claudia Wild
Journal:  Wien Med Wochenschr       Date:  2019-02-06

Review 4.  "Ready for the future?" - Status of national and cross-country horizon scanning systems for medicines in European countries.

Authors:  Sabine Vogler
Journal:  Ger Med Sci       Date:  2022-03-31

5.  Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System.

Authors:  Irene Eriksson; Mia von Euler; Rickard E Malmström; Brian Godman; Björn Wettermark
Journal:  Appl Health Econ Health Policy       Date:  2019-02       Impact factor: 2.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.